Antibiotics Resistance of Stenotrophomonas Maltophilia Strains Isolated from Various Clinical Specimens

Overview

Journal Afr Health Sci

Date 2016 Jul 1

PMID 27358626

Citations 18

Authors

Aytekin Cikman

Mehmet Parlak

Yasemin Bayram

Huseyin Guducuoglu

Mustafa Berktas

Affiliations

Soon will be listed here.

Abstract

Background: A limited number of antibiotics are recommended for the therapy of Stenotrophomonas maltophilia infections due to therapy difficulties caused by its numerous mechanisms of resistance.

Objectives: In this study conducted over a period of approximately 5 years we aimed to determine resistance rates of S. maltophilia based on drug classification recommended by Clinical and Laboratory Standards Institute.

Methods: A total of 118 S. maltophilia strains isolated from various clinical specimens between January 2006 and June 2012 were included in the study. BD Phoenixautomated microbiology system (Becton Dickinson, USA) was utilized for species level identification and antibiotic susceptibility testing.

Results: Sixty seven of S. maltophilia strains were isolated from tracheal aspirate isolates, 17 from blood, 10 from sputum, 10 from wound and 14 from other clinical specimens. Levofloxacin was found to be the most effective antibiotic against S. maltophilia strains with resistance rate of 7.6%. The resistance rates to other antibiotics were as follows: chloramphenicol 18.2%, trimethoprim-sulfamethoxazole 20.3% and ceftazidime 72%.

Conclusion: The study revealed that S. maltophilia is resistant to many antibiotics. The treatment of infections caused by S. maltophilia should be preferred primarily as levofloxacin, chloramphenicol, and TMP-SXT, respectively.

Citing Articles

Clinical presentation and outcomes of bloodstream infection with intrinsically carbapenem-resistant non-fermenting gram-negative organisms: Stenotrophomonas maltophilia, Elizabethkingia spp. and Chryseobacterium spp. in Singapore, from 2012 to 2024.

Koh M, Ngiam J, Chew K, Smitasin N, Lum L, Allen D BMC Infect Dis. 2025; 25(1):273.

PMID: 40000958 PMC: 11863829. DOI: 10.1186/s12879-025-10636-9.

Temporal analysis of prevalence and antibiotic-resistance patterns in Stenotrophomonas maltophilia clinical isolates in a 19-year retrospective study.

AlFonaisan M, Mubaraki M, Althawadi S, Obeid D, Al-Qahtani A, Almaghrabi R Sci Rep. 2024; 14(1):14459.

PMID: 38914597 PMC: 11196270. DOI: 10.1038/s41598-024-65509-z.

Global mapping of antibiotic resistance rates among clinical isolates of Stenotrophomonas maltophilia: a systematic review and meta-analysis.

Bostanghadiri N, Sholeh M, Navidifar T, Dadgar-Zankbar L, Elahi Z, van Belkum A Ann Clin Microbiol Antimicrob. 2024; 23(1):26.

PMID: 38504262 PMC: 10953290. DOI: 10.1186/s12941-024-00685-4.

Evaluation of ethanol and EDTA concentrations in the expression of biofilm-producing smf-1, rpfF genes in XDR clinical isolates of Stenotrophomonas maltophilia.

Deilamani M, Nikkhahi F, Bakht M, Alizadeh S, Fardsanei F, Javadi A BMC Microbiol. 2023; 23(1):277.

PMID: 37775770 PMC: 10542227. DOI: 10.1186/s12866-023-03008-3.

In Vitro Activity of Cefiderocol against Clinical Gram-Negative Isolates Originating from Germany in 2016/17.

Wohlfarth E, Kresken M, Deuchert F, Gatermann S, Pfeifer Y, Pfennigwerth N Antibiotics (Basel). 2023; 12(5).

PMID: 37237767 PMC: 10215668. DOI: 10.3390/antibiotics12050864.

References

Araoka H, Baba M, Yoneyama A . Risk factors for mortality among patients with Stenotrophomonas maltophilia bacteremia in Tokyo, Japan, 1996-2009. Eur J Clin Microbiol Infect Dis. 2010; 29(5):605-8. DOI: 10.1007/s10096-010-0882-6. View

Krcmery Jr V, Sykora P, Trupl J, Kunova A, Sabo A, Jurga L . Antibiotic use and development of resistance in blood culture isolates: 8 years of experience from a cancer referral center. J Chemother. 2001; 13(2):133-42. DOI: 10.1179/joc.2001.13.2.133. View

Brooke J . Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev. 2012; 25(1):2-41. PMC: 3255966. DOI: 10.1128/CMR.00019-11. View

Hankiewicz-Ziolkowska K, Mikucka A, Gospodarek E . [Clinical strains isolation and antibiotic susceptibility of Stenotrophomonas maltophilia]. Med Dosw Mikrobiol. 2010; 62(2):127-34. View

Masgala A, Galani I, Souli M, Giamarellou H . Discrepancies between various methods in susceptibility testing and epidemiological analysis of Stenotrophomonas maltophilia clinical isolates. Cent Eur J Public Health. 2010; 18(2):119-23. DOI: 10.21101/cejph.a3571. View

Koseoglu O, Sener B, Gur D . [Molecular epidemiology of Stenotrophomonas maltophilia strains isolated from paediatric patients]. Mikrobiyol Bul. 2004; 38(1-2):9-19. View

Nyc O, Matejkova J . Stenotrophomonas maltophilia: Significant contemporary hospital pathogen - review. Folia Microbiol (Praha). 2010; 55(3):286-94. DOI: 10.1007/s12223-010-0043-4. View

Hancock R . Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clin Infect Dis. 1998; 27 Suppl 1:S93-9. DOI: 10.1086/514909. View

Sader H, Jones R . Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. Int J Antimicrob Agents. 2005; 25(2):95-109. DOI: 10.1016/j.ijantimicag.2004.10.002. View

10.

Falagas M, Grammatikos A, Michalopoulos A . Potential of old-generation antibiotics to address current need for new antibiotics. Expert Rev Anti Infect Ther. 2008; 6(5):593-600. DOI: 10.1586/14787210.6.5.593. View

11.

Nicodemo A, Araujo M, Ruiz A, Gales A . In vitro susceptibility of Stenotrophomonas maltophilia isolates: comparison of disc diffusion, Etest and agar dilution methods. J Antimicrob Chemother. 2004; 53(4):604-8. DOI: 10.1093/jac/dkh128. View

12.

Dizbay M, Tunccan O, Sezer B, Aktas F, Arman D . Nosocomial Burkholderia cepacia infections in a Turkish university hospital: a five-year surveillance. J Infect Dev Ctries. 2009; 3(4):273-7. DOI: 10.3855/jidc.124. View

13.

Valdezate S, Vindel A, Loza E, Baquero F, Canton R . Antimicrobial susceptibilities of unique Stenotrophomonas maltophilia clinical strains. Antimicrob Agents Chemother. 2001; 45(5):1581-4. PMC: 90512. DOI: 10.1128/AAC.45.5.1581-1584.2001. View

14.

Enoch D, Birkett C, Ludlam H . Non-fermentative Gram-negative bacteria. Int J Antimicrob Agents. 2007; 29 Suppl 3:S33-41. DOI: 10.1016/S0924-8579(07)72176-3. View

15.

Niks M, Hanzen J, Ohlasova D, Rovna D, Purgelova A, Szovenyiova Z . [Multiresistant nosocomial bacterial strains and their "in vitro" susceptibility to chloramphenicol and colistin]. Klin Mikrobiol Infekc Lek. 2004; 10(3):124-9. View

16.

Denton M, Kerr K . Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev. 1998; 11(1):57-80. PMC: 121376. DOI: 10.1128/CMR.11.1.57. View